Mounjaro® 15 mg contains tirzepatide, a dual GIP and GLP-1 receptor agonist developed to help improve blood glucose control in adults with type 2 diabetes when used alongside diet and exercise. Tirzepatide works by activating both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, supporting glucose regulation through multiple physiological pathways.
The 15 mg strength is one of the maintenance dosage options and is generally intended for patients who have completed the recommended dose-escalation schedule under the supervision of a qualified healthcare professional. Treatment is individualized based on therapeutic response, tolerability, and clinical judgment.
Each prefilled injection pen is designed for once-weekly administration according to the manufacturer’s prescribing information. Users should always follow the instructions provided by their healthcare provider and the official prescribing information.
Key Features
- Contains tirzepatide 15 mg
- Dual GIP and GLP-1 receptor agonist
- Once-weekly injectable formulation
- Prefilled, single-use injection pen
- Intended for use under medical supervision
- Prescription medicine in markets where approved
Storage
Store refrigerated according to the manufacturer’s instructions. Do not freeze. Protect from excessive heat and direct sunlight. Keep out of the reach of children.
Reviews
There are no reviews yet.